RNC Capital Management LLC Increases Stake in Gilead Sciences, Inc. $GILD

RNC Capital Management LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 451,991 shares of the biopharmaceutical company’s stock after buying an additional 6,947 shares during the quarter. Gilead Sciences comprises about 2.5% of RNC Capital Management LLC’s portfolio, making the stock its 15th biggest holding. RNC Capital Management LLC’s holdings in Gilead Sciences were worth $55,477,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Corundum Trust Company INC purchased a new position in Gilead Sciences in the 3rd quarter worth approximately $26,000. Ares Financial Consulting LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $28,000. Financial Consulate Inc. increased its holdings in shares of Gilead Sciences by 85.8% in the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares during the last quarter. North Star Investment Management Corp. lifted its position in Gilead Sciences by 54.8% during the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 86 shares in the last quarter. Finally, MTM Investment Management LLC boosted its stake in Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 176 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total value of $1,291,600.00. Following the sale, the chief executive officer owned 632,567 shares in the company, valued at approximately $81,702,353.72. The trade was a 1.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the transaction, the insider directly owned 128,779 shares in the company, valued at approximately $18,152,687.84. The trade was a 2.28% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 178,640 shares of company stock valued at $26,584,250. 0.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on GILD shares. Sanford C. Bernstein restated an “outperform” rating and issued a $160.00 target price on shares of Gilead Sciences in a report on Wednesday, February 11th. Wells Fargo & Company boosted their price target on shares of Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Citigroup upped their price objective on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a report on Monday, April 13th. Argus lifted their target price on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Finally, The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a report on Friday, April 17th. Twenty-four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $157.35.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $132.69 on Tuesday. The company’s 50 day simple moving average is $140.49 and its 200-day simple moving average is $132.55. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. Gilead Sciences, Inc. has a 1 year low of $95.29 and a 1 year high of $157.29. The company has a market capitalization of $164.70 billion, a price-to-earnings ratio of 19.60, a price-to-earnings-growth ratio of 1.74 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. During the same quarter last year, the company posted $1.90 EPS. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 8.62 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were paid a $0.82 dividend. The ex-dividend date of this dividend was Friday, March 13th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s payout ratio is presently 48.45%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.